Beximco Pharma Discussion Threads

[volsung] 12/2/2025 07:56

I am reminded of my latter days in Rhodesia circa 1965
My ball and strife was shouting at a servant whilst I shot a marauding monkey raiding our tobacco field.
A bit like this company it seems.
Oh well.

[arlington chetwynd talbott] 12/2/2025 07:50

Mine hit my interactive investor SIPP on Monday too and I duly reinvested it plus a few extra quid for a round number of shares.ReinvestSleepDream of FungibilityRepeat

[3800] 10/2/2025 15:15

My divi arrived today with ii too

[lord raster] 08/2/2025 16:47

Divi paid and in my account

[arlington chetwynd talbott] 01/2/2025 13:22

Trump is now talking about a tariff barrier for pharmaceuticals:

[arlington chetwynd talbott] 31/1/2025 12:04

Still no dividend in my interactive investor SIPP - anyone else had any luck?

[outsizeclothes.com] 30/1/2025 23:42

Looks a solid, business as usual, trading update. Happy to hold on a very low p/e, despite the politics.

[arlington chetwynd talbott] 30/1/2025 16:32

RNS Number : 3393VBeximco Pharmaceuticals Ltd30 January 2025 30 January 2025BEXIMCO PHARMACEUTICALS LIMITEDPayment of Cash DividendBeximco Pharmaceuticals Limited ("Beximco Pharma", "BPL" or "the Company"; AIM Symbol: BXP, LEI No.: 213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces that the 40% cash dividend of the nominal value per ordinary share/GDR (Taka 4.00 per ordinary share/GDR) for the year ended 30 June 2024, which was approved in the Annual General Meeting ("AGM") held on 29 December 2024, has been deposited with the custodian bank (HSBC) in Dhaka on 26 January 2025 and subsequently credited to the Depository.For any queries regarding the credit of dividend to respective accounts of holders of GDRs, please contact the Depository (The Bank of New York Mellon) representative, Mr. Vinu Kurian, at [e-mail].

[arlington chetwynd talbott] 29/1/2025 07:19

Solid HY results.

[arlington chetwynd talbott] 29/1/2025 00:10

They do seem to have form here, so maybe no need to worry. When it does finally appear, one to reinvest, I think.ReinvestSleepDream of FungibilityRepeat

[arlington chetwynd talbott] 28/1/2025 10:54

Nothing in my ii account yet. Anyone else had any luck?

[outsizeclothes.com] 14/1/2025 17:47

The imho conservative way that BXP is run, it shouldn't matter if there were 2 or 3 more independent directors. There's nothing to hide.
But no company could operate with a majority, (I presume voting) of 3rd party directors in place to defacto run the Company.
It makes you wonder what the Govt. has to fear?
Or it is just to stop the Company recklessly bailing out the former Chairman in some shoddy, underhand way?
I would have thought the Govt. should be quite happy with the tax the Company pays, AND the slug of tax they get from our divvys.

[arlington chetwynd talbott] 14/1/2025 11:51

Not great to hear that BXP still seems to be in the crosshairs. But I am sticking with it.

[3800] 11/1/2025 13:51

No div here yet at ii. it was 12th Feb last year

[live ink] 11/1/2025 07:39

Gentlemen,

Has the dividend turned up yet?

Live Ink

[arlington chetwynd talbott] 30/12/2024 12:14

Now back up to where it was for most of the last couple of years. Hopefully the momentum that has brought it back up here will take it a bit further.

[someuwin] 19/11/2024 09:10

Notice of AGM. Nothing out of the ordinary - business as usual which is good.

Name changing from Beximco Pharmaceuticals Limited to Beximco Pharmaceuticals PLC. Maybe to emphasise its independence from the parent company?

[arlington chetwynd talbott] 15/11/2024 13:35

"A storm in a Bangladesh teacup. Cue a rerating on great results and loss of fear."I think outsizedclothes is closer to the mark with "so far so good". Encouraging results though, certainly.

[outsizeclothes.com] 14/11/2024 22:01

On the first quarter numbers (which, like the full year, are again good imho):-

Beximco Pharma Managing Director, Iqbal Ahmed, commented:
"We have started the year with modest revenue growth in the face of ongoing macroeconomic challenges. However, as demonstrated in our recent strong full year results, through the resilience and underlying strengths of the business, we remain confident in executing on our growth strategy by providing high-quality and affordable medicines to patients, and ultimately delivering value for shareholders."

This announcement is available in its entirety at

NET ASSET VALUE 101 TAKA = 67p Sterling

[microscope] 13/11/2024 22:54

Yeah very fair points outsize. Undoubtedly the price could fall too far too fast if they're forced to sell for no business reasons, and the buying opportunity would become irresistible.

[outsizeclothes.com] 13/11/2024 17:42

Agreed Microscope. Indebted individual holders being forced to sell is a definite risk, and may create a great value 'buyers market' in the short term, IF it were to happen.
On a theoretical upside, such forced sellers could also be pounced on by any potential predator looking at building a stake at deep value levels.

[microscope] 13/11/2024 10:27

The fact that the shares though were suspended would suggest some knock-on effect, hopefully minimal. I suspect that could be that if a receiver were appointed, they may force the individuals with holdings here to sell at whatever price the market was willing to accept.

I'm a bit risk-averse just now so personally I'm going to watch until a final judgement in the next 14 days is announced.

[greg the grinch] 12/11/2024 23:48

A storm in a Bangladesh teacup. Cue a rerating on great results and loss of fear.

45p by Xmas is my best tealeaves-inspired guess.

[outsizeclothes.com] 12/11/2024 22:39

The way I see it is "so far so good"
Beximco Pharma is NOT Beximco Group, and is a stand alone entity with regards to loan Capital and shareholders registrar, and it's debt is Company specific.
The parent Company is at most an indirect minority holder in Pharma through the holdings of individuals, and Pharma's management is separate - except for the Chair - who hadn't a day-to-day running of the Company role.